BCL6 and non-Hodgkin lymphoma: Clinical trials are currently underway to evaluate PROTAC-based BCL6 inhibitors in the context of relapsed/refractory NHL, such as ARV-393 (Arvinas, phase 1, NCT06393738) and BMS-986458 (Bristol-Myers-Squibb, phase 1/2, NCT06090539).